authors
- Chi, KN
- Taavitsainen, S
- Iqbal, N
- Ferrario, C
- Ong, M
- Wadhwa, D
- Hotte, Sebastien
- Lo, G
- Tran, B
- Azad, A
- Wood, L
- Gingerich, JR
- North, S
- Pezaro, CV
- Ruether, D
- Sridhar, SS
- Annala, M
- Bacon, J
- Wyatt, AW
A randomized phase II study of cabazitaxel (CAB) vs (ABI) abiraterone or (ENZ) enzalutamide in poor prognosis metastatic castration-resistant prostate cancer (mCRPC)
Conferences
- Overview
- Research
- Identity
- Additional Document Info
- View All
Overview
status
publication date
- October 2018
has subject area
- 1112 Oncology and Carcinogenesis (FoR)
- Oncology & Carcinogenesis (Science Metrix)
published in
- Annals of Oncology Journal
presented at event
- 43rd ESMO Congress (ESMO) Conference